Aetion’s Acquisition of Replica Analytics

Lowenstein represented Aetion in the acquisition of Replica Analytics, assisted by Fasken Martineau DuMoulin LLP.

Aetion, the leading regulatory-grade real-world evidence (RWE) technology provider, executed its acquisition of Replica Analytics, a pioneer in using artificial intelligence (AI) for synthetic health data generation.

Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. 

Replica Analytics is a developer of unique technologies for generating privacy protective synthetic data that maintains the statistical properties of real data. The Replica Synthesis software provides a full suite of synthetic data generation and evaluation capabilities that can solve multiple grand challenges facing the life sciences industry, and health research in general. 

The Lowenstein deal team included Anthony O. Pergola (Picture), Mark P. Kesslen, Sarah Gore, and Adam Dickson.

The Fasken team was led by Iain Mant and Adrian Wan, which included Clara Rozee, Myriam Gonzalez, Virginia Schweitzer (M&A), Bonny Mak (Employment), Mike Coburn (Tax), Lorene Novakowski (Privacy and Employment) and Peter Cheng (Student). 

Involved fees earner: Michael Coburn – Fasken Martineau; Myriam Gonzalez – Fasken Martineau; Bonny Mak – Fasken Martineau; Iain Mant – Fasken Martineau; Lorene Novakowski – Fasken Martineau; Clara Rozee – Fasken Martineau; Virginia Schweitzer – Fasken Martineau; Adrian Wan – Fasken Martineau; Adam Dickson – Lowenstein Sandler; Sarah Gore – Lowenstein Sandler; Mark Kesslen – Lowenstein Sandler; Anthony Pergola – Lowenstein Sandler;

Law Firms: Fasken Martineau; Lowenstein Sandler;

Clients: Aetion; Replica Analytics;